secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001213900-25-121461
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics amends exec employment pacts; salaries raised for CEO, COO, CFO, CAO
--------------------------------------------------------------------------------

- CEO salary increased to $827,176 (+5% from $787,787); other terms unchanged.
- COO salary increased to $524,790 (+5% from $499,800); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.
- CFO salary increased to $586,940 (+5% from $558,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.
- CAO salary increased to $576,440 (+5% from $548,990); new severance: 12 months lump sum on non-cause termination, 18 months on CIC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025121461/0001213900-25-121461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025121461/ea0269660-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-121461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer